Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Other neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 425Leukemia, Myeloid, Acute 351Leukemia 240Leukemia, Myelogenous, Chronic, BCR-ABL Positive 232Precursor Cell Lymphoblastic Leukemia-Lymphoma 211Myeloproliferative Disorders 161Lymphoma, Non-Hodgkin 156Hodgkin Disease 135Primary Myelofibrosis 129Leukemia, Lymphocytic, Chronic, B-Cell 129Multiple Myeloma 126Leukemia, Myelomonocytic, Chronic 118Lymphoma 106Leukemia, Myeloid, Chronic-Phase 78Lymphoma, Mantle-Cell 76Lymphoma, Follicular 71Congenital Abnormalities 69Blast Crisis 69Lymphoma, Large B-Cell, Diffuse 67Leukemia, Myeloid, Accelerated Phase 66Polycythemia Vera 64Lymphoma, B-Cell, Marginal Zone 64Burkitt Lymphoma 63Hematologic Neoplasms 53Anemia, Refractory, with Excess of Blasts 52Lymphoma, Large-Cell, Immunoblastic 51Neoplasms, Plasma Cell 47Myelodysplastic-Myeloproliferative Diseases 44Thrombocythemia, Essential 40Recurrence 40

Interventions

ruxolitinib 1CPI-0610 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Preleukemia × Myeloid × Clear all
NCT02158858 2026-06-04

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled 61 charts
MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡